Icahn School of Medicine at Mount Sinai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Icahn School of Medicine at Mount Sinai sits in the top decile of US sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count).
Icahn School of Medicine at Mount Sinai: 708 sponsored US clinical trials, 163 recruiting.
Icahn School of Medicine at Mount Sinai sponsors 708 registered US clinical trials on ClinicalTrials.gov, 163 of them currently recruiting, and 423 completed. 88 of these trials are in Phase 3-4 (later-stage) and 138 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 7 trials.
Top-decile sponsor footprint
Icahn School of Medicine at Mount Sinai ranks in the top decile of sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
423 of 499 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
708 total, page 2 of 15
Cannabidiol in Sickle Cell Disease
NCT06930703
Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
NCT05519111
Quantitative Xylazine Measurement in ED
NCT06949605
Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions
NCT06892691
NIOSH R21 WTC Asthma
NCT07222501
Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy
NCT06653400
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
NCT06592833
Resilient Together for Dementia (RT-D)
NCT06619327
Evaluation of the Abbott i-STAT TBI Biomarker Test
NCT06766435
Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD
NCT06780709
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
NCT06559826
Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
NCT06941467
Surveillance Versus Bronchoscopy After Airway Stenting
NCT06935695
Cocaine Cue-reactivity Incubation Study
NCT07091877
Building Community Resilience Program
NCT06771167
Cognitive Reappraisal Training for Borderline Personality (BPD)
NCT06772831
Behavioral Therapy for Crohn's Disease
NCT06512597
tVNS in Long COVID-19
NCT06585254
Skin Pigment/Pulse Oximeter in Congenital Heart Disease (CHD)
NCT06575270
SCM Muscle as a Marker for Frailty in Patients Undergoing ENT Surgery
NCT06704256
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
NCT06040970
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT06511050
Vagal Nerve Stimulation in Enhanced Stroke Recovery: The VALOR Registry
NCT05694663
High Fructose Diet, the Gut Microbiome, and Metabolic Health
NCT06329544
Sana Device for Post-Treatment Lyme Disease Syndrome Chronic Pain
NCT06655844
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
NCT06541249
Antiviral Clinical Trial for Long Covid-19
NCT06511063
Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management
NCT06634810
Asthma Symptom Perception Study
NCT06612294
Intrathecal Dexmedetomidine vs Epinephrine
NCT06418308
The Prevent Coronary Artery Disease Trial
NCT06494501
Methamphetamine Cue-reactivity
NCT07086014
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
NCT06373458
Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion
NCT06689176
Rectus Sheath Block in Cardiac Surgery
NCT05833048
Precision Medicine Study
NCT06338150
Dupilumab in the Treatment of Pediatric Alopecia Areata
NCT05866562
Neurosteer Bedside Monitoring System
NCT06718764
Different Medications to Induce Labor
NCT06259097
USCOM in Newly Diagnosed FGR Cases
NCT06343051
Bimekizumab in Plaque Psoriasis
NCT06336343
Neurofeedback During Eating for Bulimia Nervosa
NCT05614024
Investigation of a 3 oz Water Protocol on Patients With Tracheostomies
NCT06120790
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
NCT06405828
Psychopharmacological Treatment of Emotional Distress
NCT06133114
A Study of Meaning-Centered Psychotherapy for Caregivers to People With Cancer
NCT06307535
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
NCT06088771
Neural Circuit Effects of Ketamine in Depression
NCT06213324
Social Isolation and Aging in Schizophrenia
NCT07419321
MTC Versus FMT in for RCDI
NCT05911997
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 81 |
| Phase 3 | 21 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Icahn School of Medicine at Mount Sinai pipeline
163 recruiting of 708 indexed (23% open); 423 completed (60%).
Phase mix: 88 late (III/IV) vs 138 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Icahn School of Medicine at Mount Sinai: open-pipeline peers nationwide
Peers matched on 708 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 708 trials (± recruiting share)
- Sanofi · 713 trials · 10% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- University of Miami · 721 trials · 20% recruiting
- The Cleveland Clinic · 688 trials · 14% recruiting
Sponsors near 23% open enrollment (± trial volume)
- Clemson University · 23% recruiting · 13 trials
- Liberating Technologies · 23% recruiting · 13 trials
- Rahul Aggarwal · 23% recruiting · 13 trials
- Sequenom · 23% recruiting · 26 trials
Related
What to do with this Icahn School of Medicine at Mount Sinai page
708 registered trials is a research-attention snapshot, not an endorsement of Icahn School of Medicine at Mount Sinai or any single study.
- 163 of Icahn School of Medicine at Mount Sinai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Icahn School of Medicine at Mount Sinai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Icahn School of Medicine at Mount Sinai pipeline card: 708 registered trials from official public datasets.Report a data error.